Comparative Pharmacology
Head-to-head clinical analysis: FEMSTAT versus KERYDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEMSTAT versus KERYDIN.
FEMSTAT vs KERYDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FEMSTAT (butoconazole) is an imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death.
KERYDIN (tavaborole) is a boron-based antifungal that inhibits fungal protein synthesis by blocking the activity of leucyl-tRNA synthetase, thereby preventing aminoacylation of tRNA(Leu) and impairing protein synthesis in dermatophytes.
Butoconazole nitrate 2% vaginal cream: one applicatorful (approximately 5 g) intravaginally at bedtime for 3 days. Alternatively, butoconazole nitrate 2% single-dose vaginal cream: one applicatorful (approximately 5 g) intravaginally as a single dose.
8 mg/kg (max 800 mg) IV over 2 hours once daily for 14 days
None Documented
None Documented
Terminal half-life: 6-9 hours; clinical context: supports twice-daily dosing for consistent therapeutic levels.
Terminal elimination half-life is approximately 24 hours, supporting once-daily topical application.
Primarily hepatic metabolism; <10% excreted unchanged in urine. Fecal excretion accounts for approximately 30% of metabolites.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 88% of the dose, with negligible fecal excretion (<1% as unchanged drug).
Category C
Category C
Antifungal
Antifungal